Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Vera Therapeutics' Trutakna (atacicept) receives FDA accelerated approval for IgA nephropathy targeting APRIL and BAFF
Protein therapy, kidney disease, fusion protein, IgA nephropathy, APRIL/BAFF inhibitor, accelerated approval - Read more

AstraZeneca, Sino Biopharmaceutical strike ex-China licensing deal for COPD candidate TQC3721, $200M upfront, up to $1.9B total
Licensing deal, respiratory disease, small molecule, milestone payments, commercialization - Read more

Helix, AstraZeneca partner on multi-year clinico-genomic data access deal to accelerate drug discovery and development
Research collaboration, drug discovery, genomics, cardiometabolic, autoimmune, data analytics - Read more

Catalent, Nanoscope Therapeutics expand partnership for late-phase and commercial supply of MCO-010
Manufacturing agreement, gene therapy, ophthalmology, commercialization, rare disease - Read more

Boehringer Ingelheim licenses Prime Vector Technologies' ORFV platform for off-the-shelf cancer vaccines, milestones and royalties undisclosed
Licensing deal, oncology, vaccine, viral vector, milestone payments, royalties - Read more

Codis acquires Catalent's Nottingham facility for oral solid dose and spray dry solutions
Acquisition, manufacturing, small molecule, oral solid dose - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Satellos Bioscience Ph1 data show (SAT-3247) reduces fat fraction in adults with Duchenne muscular dystrophy
Small molecule, neuromuscular disease, Duchenne muscular dystrophy, AAK1 inhibitor, muscle regeneration - Read more

Leo Cancer Care secures $65M Series D to scale upright radiotherapy treatment system
Oncology, radiotherapy, medical devices, manufacturing - Read more

MeiraGTx gains up to $400M from Oberland Capital to support eye gene therapy launches
Gene therapy, rare disease, ophthalmology, clinical-stage, AAV - Read more

Fore Biotherapeutics raises $67.4M Series D-2 extension, advancing BRAF inhibitor plixorafenib development
Oncology, small molecule, CNS tumors, rare disease, clinical-stage - Read more

Healome Therapeutics closes £2M ($2.7M) seed round to advance eye-drop matrix technology for ocular surface diseases
Ocular surface disease, drug delivery, small molecule, biologics, preclinical, rare disease - Read more

Panakès Partners holds first close of BII Catalyst Fund I for Italy at €20M ($22.8M), backing early-stage therapeutics startups
Life sciences, venture capital, early-stage, therapeutics - Read more

Bone Biologics plans up to $9M private placement, funding spine fusion orthobiologic development
Orthobiologics, spine fusion, clinical-stage, small molecule - Read more

Evonik invests $100M in Indiana API plant to meet surging U.S. CDMO demand
Small molecule, CDMO, manufacturing, strategic - Read more

Prime Medicine wins arbitration against Beam Therapeutics, retaining rights to develop AATD gene therapy PM647
Prime editing, rare disease, strategic, competitive - Read more

Caidya, Simbec-Orion unite to form global CRO platform spanning Europe, Americas, Asia-Pacific
Contract research organization, oncology, rare disease, major transaction - Read more

Scipher Medicine merges with Chemomab Therapeutics in all-stock deal, gains Nasdaq listing to advance RA drug nebokitug
Monoclonal antibody, autoimmune, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here